Clinical Trials Logo

Clinical Trial Summary

The purpose of this multicenter, prospective and observational registry is to evaluate the safety and efficacy of TAVR for treatment of pure severe aortic valve regurgitation. Baseline characteristics, procedural and clinical data will be collected


Clinical Trial Description

Pure native aortic valve regurgitation (NAVR) is a multifactorial valvular disease, with a prevalence of moderate or severe NAVR ranging from 0.5% to 2.7%. Patients with severe NAVR have a poor prognosis, conservative management has a 1-year mortality rate of more than 20%. Currently, surgical aortic valve replacement (SAVR) is the recommended treatment strategy for patients with NAVR. However, data showed that only 20% of patients with severe NAVR and left-ventricular ejection fraction (LVEF) of 30-50% undergo SAVR, while only 3% of those with an LVEF below 30% receive SAVR. Therefore, a less invasive surgical alternative therapy is needed for high surgical-risk patients from SAVR. Transcatheter aortic valve replacement (TAVR) is now considered the first-choice treatment for elderly patients with aortic stenosis, regardless of surgical risk. Recently, it has also been used to treat patients with NAVR in an "off-label" setting. The latest European guidelines suggest that TAVR may be considered in experienced centers for selected patients with AR who are not eligible for SAVR. However, the role of TAVR in patients with severe NAVR is still debatable. Current studies on this topic are limited by their retrospective design and small sample sizes. Dedicated devices for aortic regurgitation, such as the JenaValve, have shown promising results in terms of technical success and short-term outcomes. However, TAVR for patients with NAVR using on-label devices has a relatively high rate of pacemaker implantation. Additionally, the dedicated device was designed only for tricuspid valve anatomy, making TAVR with off-label devices the main invasive strategy for high-surgical risk patients with bicuspid valves. It's worth noting that the dedicated device is not yet commercially available worldwide. Therefore, further investigation into TAVR using off-label devices for NAVR patients, including those with bicuspid and tricuspid valves, is necessary. The objective of this study was to evaluate the safety and efficacy of TAVR in patients with NAVR in a real-world setting. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06381271
Study type Observational
Source Xijing Hospital
Contact Rutao Wang, M.D, Ph.D
Phone +86-15091095796
Email rutaowang@qq.com
Status Recruiting
Phase
Start date October 30, 2018
Completion date October 2034

See also
  Status Clinical Trial Phase
Recruiting NCT05438862 - Early Aortic vaLve surgEry Versus wAtchful waitiNg Strategy in Severe Asymptomatic aOrtic reguRgitation N/A
Completed NCT03644784 - Protocoled Quantitative Assessment of Aortic Regurgitation Using Videodensitometry in a Multicontinental Trial in Rotterdam, Montreal, Yamaguchi, Segeberg, Amsterdam.
Recruiting NCT04797572 - Clinical Evaluation of the Free Margin Cusp Sizer (CALIBRATE) N/A
Not yet recruiting NCT05536310 - TAVIS Registry - Trilogy Heart Valve System for Management of Patients With Aortic Valve Disease
Completed NCT02375282 - Physical and Functional Recovery From Cardiac Surgery in Hospitalized Patients: A Feasibility Pilot Study N/A
Completed NCT04548726 - Hemodynamic Matched Comparison of the Balloon-Expandable Transcatheter Heart Valves Myval and Sapien-3 for the Treatment of Aortic Stenosis
Not yet recruiting NCT06455787 - J-Valve Transfemoral Pivotal Study N/A
Completed NCT01593917 - Trifectaâ„¢ Long Term Follow-Up (LTFU) Study
Recruiting NCT05459233 - Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR N/A
Recruiting NCT05902897 - Aortic or Mitral Valve Replacement With the Braile Biomédica® Bovine Pericardium Valvular Bioprosthesis
Completed NCT03807921 - Anticoagulation for Aortic Bioprosthesis (ANTIPRO) Phase 4
Recruiting NCT04464655 - A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease
Recruiting NCT05799573 - CT Scan Sizing for Perceval Sutureless Valve
Completed NCT00636987 - Aortic or Mitral Valve Replacement With the Biocor and Biocor Supra N/A